• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    11/14/24 4:31:20 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    SC 13G/A 1 tm2428252d4_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    Kymera Therapeutics, Inc.

    (Name of Issuer)

     

    COMMON STOCK, $0.0001 PAR VALUE

    (Title of Class of Securities)

     

    501575104

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     CUSIP No. 501575104 Page 2 of 10 Pages

     

    1.

    Name of Reporting Persons

    Atlas Venture Fund X, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,173,216(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,173,216(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,173,216(1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.4%(2)

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1) As described in Item 4 below, Atlas Venture Fund X, L.P., a Delaware limited partnership (“Atlas X”) directly holds 4,173,216 shares of the Issuer’s Common Stock. Atlas Venture Associates X, L.P., a Delaware limited partnership (“AVA X LP”) and Atlas Venture Associates X, LLC, a Delaware limited liability company (“AVA X LLC” and together with Atlas X and AVA X LP, the “Fund X Reporting Persons”) beneficially own the shares of the Issuer’s Common Stock held by Atlas X. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X. As such, each of the Fund X Reporting Persons share voting and dispositive power with respect to the shares held by Atlas X.

     

    (2) This percentage is calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.

     

     

     

     CUSIP No. 501575104 Page 3 of 10 Pages

     

    1.

    Name of Reporting Persons

    Atlas Venture Associates X, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,173,216(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,173,216(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,173,216(1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.4%(2)

    12.

    Type of Reporting Person (See Instructions)

    PN

      

    (1) As described in Item 4 below, Atlas X directly holds 4,173,216 shares of the Issuer’s Common Stock. AVA X LP and AVA X LLC beneficially own the shares of the Issuer’s Common Stock held by Atlas X. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X. As such, each of the Fund X Reporting Persons share voting and dispositive power with respect to the shares held by Atlas X.

     

    (2) This percentage is calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.

     

     

     

     CUSIP No. 501575104 Page 4 of 10 Pages

     

    1.

    Name of Reporting Persons

    Atlas Venture Associates X, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,173,216(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,173,216(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,173,216(1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    6.4%(2)

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1) As described in Item 4 below, Atlas X directly holds 4,173,216 shares of the Issuer’s Common Stock. AVA X LP and AVA X LLC beneficially own the shares of the Issuer’s Common Stock held by Atlas X. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X. As such, each of the Fund X Reporting Persons share voting and dispositive power with respect to the shares held by Atlas X.

     

    (2) This percentage is calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.

     

     

     

     CUSIP No. 501575104 Page 5 of 10 Pages

     

    1.

    Name of Reporting Persons

    Atlas Venture Opportunity Fund I, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    723,246(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    723,246(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    723,246(1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    1.1%(2)

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1) As described in Item 4 below, Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership (“AVO I”) directly holds 723,246 shares of the Issuer’s Common Stock. Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership (“AVAO LP”) and Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company (“AVAO LLC” and together with AVO I and AVAO LP, the “Opportunity Fund Reporting Persons”) beneficially own the shares of the Issuer’s Common Stock held by AVO I. AVAO LP is the general partner of AVO I and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVO I. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVO I.

     

    (2) This percentage is calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.

     

     

     

     CUSIP No. 501575104 Page 6 of 10 Pages

     

    1.

    Name of Reporting Persons

    Atlas Venture Associates Opportunity I, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    723,246(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    723,246(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    723,246(1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    1.1%(2)

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1) As described in Item 4 below, AVO I directly holds 723,246 shares of the Issuer’s Common Stock. AVAO LP and AVAO LLC beneficially own the shares of the Issuer’s Common Stock held by AVO I. AVAO LP is the general partner of AVO I and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVO I. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVO I.

     

    (2) This percentage is calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.

     

     

     

     CUSIP No. 501575104 Page 7 of 10 Pages

     

    1.

    Name of Reporting Persons

    Atlas Venture Associates Opportunity I, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    723,246(1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    723,246(1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    723,246(1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    1.1%(2)

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1) As described in Item 4 below, AVO I directly holds 723,246 shares of the Issuer’s Common Stock., AVAO LP and AVAO LLC beneficially own the shares of the Issuer’s Common Stock held by AVO I. AVAO LP is the general partner of AVO I and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVO I. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVO I.

     

    (2) This percentage is calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.

     

     

     

     CUSIP No. 501575104 Page 8 of 10 Pages

     

    Item 1(a) Name of Issuer

     

    Kymera Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices

     

    200 Arsenal Yards Blvd., Suite 230
    Watertown, MA 02472

     

    Item 2(a) Name of Person Filing

     

    This Schedule 13G is filed by (i) Atlas Venture Fund X, L.P., a Delaware limited partnership (“Atlas X”), (ii) Atlas Venture Associates X, L.P., a Delaware limited partnership (“AVA X LP”), (iii) Atlas Venture Associates X, LLC, a Delaware limited liability company (“AVA X LLC” and together with Atlas X and AVA X LP, the “Fund X Reporting Persons”), (iv) Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership (“AVO I”), (v) Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership (“AVAO LP”) and (vi) Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company (“AVAO LLC” and together with AVO I and AVAO LP, the “Opportunity Fund Reporting Persons” and together with the Fund X Reporting Persons, the “Reporting Persons”).

     

    Item 2(b) Address of Principal Business Office or, if none, Residence

     

    300 Technology Square, 8th Floor
    Cambridge, Massachusetts 02139

     

    Item 2(c) Citizenship

     

    Each of Atlas X, AVA X LP, AVO I and AVAO LP is a Delaware limited partnership. Each of AVA X LLC and AVAO LLC is a Delaware limited liability company.

     

    Item 2(d) Title of Class of Securities

     

    Common Stock, $0.0001 par value per share

     

    Item 2(e) CUSIP Number

     

    501575104

     

    Item 3

     

    Not applicable.

     

    Item 4 Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1

     

    (a)  Amount beneficially owned: Atlas X is the record owner of 4,173,216 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X.
     
      Amount beneficially owned: AVO I is the record owner of 723,246 shares of Common Stock. AVAO LP is the general partner of AVO I and AVAO LLC is the general partner of AVAO LP. Each of AVO I, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVO I. As such, each of AVO I, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVO I.

     

     

     

     CUSIP No. 501575104 Page 9 of 10 Pages

     

    (b)  Percent of class: Fund X Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 6.4% and 1.1%, respectively, of the Issuer’s outstanding Common Stock, which percentages are calculated based upon 64,765,274 outstanding shares of Common Stock of the Issuer as of October 25, 2024, as reported in the Issuer’s 10-Q, filed with the Securities and Exchange Commission on October 31, 2024.
     
      Collectively, the Reporting Persons beneficially own an aggregate of 4,896,462 shares of Common Stock, which represents 7.6% of the Issuer’s outstanding Common Stock. The Fund X Reporting Persons and the Opportunity Fund Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13G shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.

     

    (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote: None of the Reporting Persons have the sole power to direct the vote of the Common Stock.
     
      (ii) Shared power to vote or to direct the vote: Each Fund X Reporting Person shares power to vote or direct the vote of 4,173,216 shares of Common Stock and each Opportunity Fund Reporting Person shares power to vote or direct the vote of 723,246 shares of Common Stock.
     
      (iii) Sole power to dispose or to direct the disposition of: None of the Reporting Persons have the sole power to dispose or to direct the disposition of the Common Stock.
     
      (iv) Shared power to dispose or to direct the disposition of: Each Fund X Reporting Person shares power to dispose or to direct the disposition of 4,173,216 shares of Common Stock and each Opportunity Fund Reporting Person shares power to dispose or to direct the disposition of 723,246 shares of Common Stock.

     

    Item 5 Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6 Ownership of More than Five Percent of Another Person

     

    Not applicable.

     

    Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

     

    Not applicable.

     

    Item 8 Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9 Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10 Certification

     

    Not applicable.

     

     

     

     CUSIP No. 501575104 Page 10 of 10 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    ATLAS VENTURE FUND X, L.P.
     
    By: Atlas Venture Associates X, L.P., its general partner
    By: Atlas Venture Associates X, LLC, its general partner
     
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: CFO  
     
    ATLAS VENTURE ASSOCIATES X, L.P.
     
    By: Atlas Venture Associates X, LLC, its general partner
     
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: CFO  
     
    ATLAS VENTURE ASSOCIATES X, LLC
     
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: CFO  
     
    ATLAS VENTURE OPPORTUNITY FUND I, L.P.
     
    By: Atlas Venture Associates Opportunity I, L.P., its general partner
    By: Atlas Venture Associates Opportunity I, LLC, its general partner
     
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: CFO  
     
    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.
     
    By: Atlas Venture Associates Opportunity I, LLC, its general partner
     
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: CFO  

     

    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC
     
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: CFO  

     

     

     

    EXHIBITS

     

    A: Joint Filing Agreement (Incorporated by reference to Exhibit A to the Schedule 13G/A, filed with the Securities and Exchange Commission on February 14, 2023)

     

    Get the next $KYMR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    7/30/2025$60.00Buy
    B. Riley Securities
    7/3/2025$70.00Overweight
    Morgan Stanley
    6/3/2025$79.00Equal-Weight → Overweight
    Morgan Stanley
    6/3/2025$60.00Neutral → Buy
    B. Riley Securities
    6/2/2025$51.00Neutral → Buy
    BofA Securities
    5/20/2025$55.00Buy
    Stifel
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    More analyst ratings

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

    Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early 2026 Company entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, with up to $750 million in potential total payments

    8/11/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

    WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2025 financial results on August 11, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage

    8/4/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Announces Pricing of $250 Million Public Offering

    WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr

    6/26/25 11:56:15 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bvf Partners L P/Il bought $13,955,348 worth of shares (317,167 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    7/1/25 6:41:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $28,842,000 worth of shares (655,500 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    6/30/25 8:15:05 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    8/22/24 4:03:26 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.

    SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    8/12/25 10:34:25 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Kymera Therapeutics Inc.

    10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)

    8/11/25 7:15:54 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

    8/11/25 7:10:28 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Bvf Partners L P/Il bought $13,955,348 worth of shares (317,167 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    7/1/25 6:41:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $28,842,000 worth of shares (655,500 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    6/30/25 8:15:05 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    6/26/25 9:00:17 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities resumed coverage on Kymera Therapeutics with a new price target

    B. Riley Securities resumed coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00

    7/30/25 8:20:56 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Kymera Therapeutics with a new price target

    Morgan Stanley resumed coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $70.00

    7/3/25 7:49:25 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Kymera Therapeutics from Equal-Weight to Overweight and set a new price target of $79.00

    6/3/25 7:25:17 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Financials

    Live finance-specific insights

    View All

    Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

    Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early 2026 Company entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, with up to $750 million in potential total payments

    8/11/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

    WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2025 financial results on August 11, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage

    8/4/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

    Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63% KT-621 was well-tolerated with a safety profile undifferentiated from placebo, with no serious adverse events, no severe adverse events, no treatment related adverse events in more than one subject

    6/2/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 4:31:20 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 1:22:39 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 9:30:22 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Leadership Updates

    Live Leadership Updates

    View All

    Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

    WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a

    5/30/25 4:01:00 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

    IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

    5/9/25 7:01:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

    Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline. To join the video call or view the li

    4/24/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care